Physician profile
Palpu Hazel
NPI 1518901974
$12,631.43
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,743 · 2020: $1,524 · 2021: $2,138 · 2022: $3,173 · 2023: $3,160 · 2024: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,047 · Education: $5.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,047.45 |
| Education | $5.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,554.17 | 2019-2024 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,534.90 | 2021-2024 | Caplyta |
| Corium, LLC | $1,304.09 | 2021-2024 | Azstarys |
| Abbvie INC. | $1,121.16 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,037.06 | 2019-2023 | Trintellix |
| Tris Pharma INC | $804.13 | 2019-2023 | Dyanavel Xr |
| Lundbeck LLC | $630.42 | 2019-2024 | Rexulti |
| Allergan, INC. | $573.31 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $496.00 | 2019-2023 | Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $471.52 | 2022-2024 | Auvelity |
| Ironshore Pharmaceuticals INC. | $445.53 | 2019-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $434.13 | 2019-2024 | Spravato |
| Sunovion Pharmaceuticals INC. | $396.58 | 2019-2022 | |
| Alkermes, INC. | $379.66 | 2021-2024 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $345.01 | 2021-2024 | Qelbree, Qelbree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $277.86 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Shire North American Group INC | $202.89 | 2019 | |
| Neos Therapeutics, LP | $158.33 | 2019-2023 | Adzenys Xr-Odt |
| Jazz Pharmaceuticals INC. | $123.90 | 2019-2022 | |
| Alfasigma USA, INC. | $82.48 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $70.79 | 2022-2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $55.99 | 2022 | |
| Arbor Pharmaceuticals, INC. | $37.27 | 2019 | |
| Adlon Therapeutics L.P. | $36.70 | 2021 | |
| Neurocrine Biosciences, INC. | $22.97 | 2022 | |
| Owp Pharmaceuticals, INC. | $18.73 | 2021 | |
| Eisai INC. | $15.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Palpu Hazel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.